Press Releases

Mar 11, 2023

Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank

Read More

Feb 27, 2023

Veracyte to Participate in Upcoming Investor Conferences

Read More

Feb 22, 2023

Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results

Read More

Feb 15, 2023

Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer

Read More

Feb 13, 2023

New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

Read More

Feb 06, 2023

Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023

Read More

Feb 01, 2023

Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium

Read More

Feb 01, 2023

Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules

Read More

Jan 05, 2023

C2i Genomics Announces Successful Evaluation of Whole Genome-Based Residual Disease Test Across Multiple Solid Cancer Models

Read More

Dec 15, 2022

Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis

Read More